Antibody Fragment
Drug Conjugates

Antibody Drug Conjugates (ADCs) are the next generation of antibody therapeutics allowing the specific tumour delivery of potent cytoxic payloads. These whole monoclonal antibody-based products have intrinsic failings which result in a narrow therapeutic index.

Antikor's unique OptiLink™ platform enables Fragment Drug Conjugates (FDCs) which provides a simple solution to widen the therapeutic window and so give clinicians more flexibility in treating aggressive solid tumours.

Targeting Platform
'Optilinked' FDCs

With its revolutionary and proprietary OptiLinkTM technology platform, Antikor has adopted a novel approach using much smaller antibody fragments (FDCs) which have uniquely high payload loadings and penetrate tumours more rapidly, so proving more efficacious, but which clear rapidly from normal tissues, so reducing side-effects.

Thus, Antikor's FDCs have a much wider therapeutic window than conventional ADCs and could revolutionise the way we treat solid tumours. 

Discovery Engine
And Products

Antikor’s proprietary antibody fragment frameworks, optimised for maximal DAR and FDC manufacturing properties, can be used to discover novel FDCs to any given target.

This makes the Antikor FDC discovery engine a valuable asset in its own right and the source of future, exciting new products.  

We're attending...

A Brief History

Antikor - Creating Antibody Drug ConjugatesAntikor Ltd is a newly established company that is exploiting a novel technology platform called OptiLinked-FDCs, to generate revolutionary products to treat solid cancers. We are a multidisciplinary spin-out from Imperial College London UK now based at the Stevenage Bioscience Catalyst. The Company has over 15 years of pioneering experience in the area of small-format, antibody fragment drug conjugates, and has generated product candidates with optimal pharmacokinetics, pharmacodynamics and other encouraging preclinical data.

Current
News

Partnering
Opportunities

Antikor is looking for commercial partners with existing or future interests in the ADC space, particulary oncology. We can offer a range of flexible models for collaboration where each party adds value to each other's technology

Are you seeking :-

Do you have:-

If the answer to any of these questions is yes, then please contact us to initiate a collaboration and licensing dialogue on Antikor's OptiLink technology platform

Scientific
Publications

View All